Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Holding EXAS?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.33Last Year’s EPS
-$0.27Same Quarter Last Year
Strong Buy
Based on 19 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2024
|% Change Since: -16.93%
|Next Earnings Date:Feb 25, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, profitability, and operational achievements, including the FDA approval of Cologuard Plus. However, execution challenges, particularly in Cologuard order growth, hurricane impacts, and transitional issues in Precision Oncology, weighed on the company's outlook for the rest of the year.Company Guidance
During the Exact Sciences Third Quarter 2024 earnings call, the company provided guidance for the remainder of the year, highlighting several key metrics and expectations. The company anticipates full-year revenue to be between $2.73 billion and $2.75 billion, with Screening revenue projected to range from $2.08 billion to $2.095 billion, and Precision Oncology revenue between $650 million and $655 million. They revised their adjusted EBITDA guidance to be between $310 million and $320 million, implying a full-year adjusted EBITDA margin expansion to 11.5%. Despite challenges in the third quarter, including the impact of Hurricanes Helene and Milton and slower-than-expected Cologuard growth, Exact Sciences expects growth to accelerate in 2025, driven by new product launches, including Cologuard Plus, and ongoing improvements in commercial execution.Revenue Growth
Total revenue grew 13% year-over-year to $709 million. Screening revenue increased by 15% to $545 million, driven by Cologuard volume.
Profitability and Cash Flow
Adjusted EBITDA expanded by 75% year-over-year to $99 million. The adjusted EBITDA margin increased by 500 basis points to 14%. The company generated a record $113 million in free cash flow.
Cologuard Plus FDA Approval
Received FDA approval for Cologuard Plus, the next-generation Cologuard test, which sets a new performance standard with 95% cancer sensitivity and 94% specificity.
Oncotype DX International Expansion
Oncotype DX revenue grew 28% internationally, contributing to the overall 5% growth in Precision Oncology revenue.
Rescreening Opportunities
The opportunity to rescreen patients continues to increase, with the number of people due for their next Cologuard test growing from 1.6 million in 2024 to 2.6 million by 2026.
---
EXAS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EXAS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $71.51 | $54.72 | -23.48% |
| Jul 31, 2024 | $45.68 | $57.91 | +26.77% |
| May 08, 2024 | $59.48 | $54.15 | -8.96% |
| Feb 21, 2024 | $63.29 | $59.49 | -6.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Exact Sciences Corp. (EXAS) report earnings?
Exact Sciences Corp. (EXAS) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Exact Sciences Corp. (EXAS) earnings time?
Exact Sciences Corp. (EXAS) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXAS EPS forecast?
EXAS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.33.
---